Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Myovant Sciences

Myovant Sciences

Myovant Sciences delivers comprehensive and innovative endometriosis treatment for women and prostate cancer solutions for men.

Myovant Sciences is a biopharmaceutical company developing innovative treatment solutions for women's health conditions and endocrine-related disorders.

Myovant Sciences developed Relugolix, a once-daily oral medication developed to reduce testosterone production in men with prostate cancer, as testosterone enables and promotes prostate cancer growth. Relugolix is also believed to be effective in women experiencing Endometriosis and uterine fibroids, other testosterone-driven ailments.

The FDA has approved a priority review of Relugolix for the indication of prostate cancer treatment, however, will not yet be reviewing the effectiveness in women.

Relugolix (USA) development pipeline, graphic courtesy of Myovant Sciences

Relugolix (Japan) development pipeline, courtesy of Myovant Sciences

Myovant is presently developing an additional pharmaceutical therapy called MVT-602, this medication is intended to trigger egg maturation in women undergoing fertility treatments, including IVF (in vitro fertilization). This treatment is moving towards phase three before submission to the FDA for approval.

MVT-602 development pipeline, courtesy of Myovant Sciences

Myovant Sciences is a publically traded company with the ticker (MYOV) and can be traded on the NYSE and NASDAQ markets.

On August 5, 2020 Myovant announced $200 Million in Post-IPO Debt funding from Dainippon Sumitomo Pharma, a Japanese pharmaceutical company.

Timeline

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Mark Terry
June 1, 2021
BioSpace
The U.S. FDA is starting off the summer months with a busy week after the Memorial Day holiday in the U.S. Here's a look.
Brandon May
May 27, 2021
BioSpace
The U.S. FDA has granted approval to MYFEMBREE, Myovant Sciences, and Pfizer's once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
BioSpace
May 21, 2021
BioSpace
CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe Relugolix combination tablet for uterine fibroids is also under U.S. FDA review with a target action date of June 1, 2021
BioSpace
May 10, 2021
BioSpace
Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions
Amirah Al Idrus
January 4, 2021
FierceBiotech
On the heels of its first approval, Myovant Sciences is tapping a new CEO to take that drug to market while stoking its R&D engine to find its successors. Dave Marek takes over from Lynn Seely, M.D., the company's chief since June 2016.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.